TEVA Teva Pharmaceutical Industries Limited
USHealthcareAs of 2026-10-16 12:11
Why TEVA matters now
Teva Pharmaceutical Industries Limited (TEVA) is a US stock in Healthcare. The latest InvestLog snapshot shows $41.17 with +0.13% on the session and $47.97B in market capitalization; recent performance reads 1-month -7.60% and YTD +0.87%.
The latest financial table shown here is Q1 2026, with revenue of $3.98B, net income of $369.0M, and EPS of $0.31. Investors can compare that operating picture with valuation signals such as P/E 24.24 and FCF yield 5.1%.
InvestLog's latest related AI research is a Rating Change note titled "TD Cowen initiates coverage of TEVA with Buy". The latest indexable market news headline is "Teva to Host R&D Day on Wednesday, November 11 in New York City" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $40.00; recent insider activity includes Kalif Eliyahu Sharon filing S-Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
24.24
PEG
0.13
P/B
4.44
P/S
2.13
EV/EBITDA
15.20
DCF Value
$21.73
FCF Yield
5.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
52.0%
Operating Margin
19.4%
Net Margin
9.0%
ROE
20.8%
ROA
3.9%
ROIC
11.5%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $3.98B | $369.0M | $0.31 |
| Q4 2025 | $4.71B | $480.0M | $0.41 |
| FY 2025 | $17.26B | $1.41B | $1.20 |
| Q3 2025 | $4.48B | $433.0M | $0.37 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$40.00
Target (Median)
$40.00
Target Range
$36.00 - $42.00
Trading Activity
Insider Trades
Related AI Research
TD Cowen initiates coverage of TEVA with BuyTD Cowen 首次覆盖 梯瓦制药公司 (TEVA),初始评级 买入(Buy)
On 2026-10-01, TD Cowen initiated coverage of TEVA with a Buy rating.TD Cowen 于 2026-10-01 首次覆盖 TEVA,初始评级为 买入(Buy)。
Oppenheimer initiates coverage of TEVA with OutperformOppenheimer 首次覆盖 梯瓦制药公司 (TEVA),初始评级 跑赢大市(Outperform)
On 2026-09-23, Oppenheimer initiated coverage of TEVA with a Outperform rating.Oppenheimer 于 2026-09-23 首次覆盖 TEVA,初始评级为 跑赢大市(Outperform)。
Mignone Roberto sells $14.4M of TEVAMignone Roberto 内部减持 梯瓦制药公司 (TEVA) $14.4M
Mignone Roberto (Director) sold 367,600 shares of Teva Pharmaceutical Industries Limited (TEVA) on 2026-09-18, at an average price of $39.06, for approximately $14.4M.Mignone Roberto(Director)于 2026-09-18 卖出 Teva Pharmaceutical Industries Limited(TEVA)367,600 股,平均价格 $39.06,合计约 $14.4M。该交易于 2026-09-22 通过 SEC 原始 Form 4 披露。
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
IL
Exchange
—
Beta
0.85
Teva Pharmaceutical Industries Limited functions as a global pharmaceutical enterprise, involved in the conception, manufacturing, marketing, and provision of a broad spectrum of generic, specialty, and biopharmaceutical products throughout North America, Europe, and various international markets. The company's diverse product range includes sterile items, hormones, potent drugs, and cytotoxic agents, available in numerous forms like tablets, capsules, injectable solutions, inhalable preparations, liquids, transdermal patches, topical ointments, and creams. Additionally, Teva develops, produces, and sells active pharmaceutical ingredients (APIs). The firm prioritizes several key therapeutic domains: central nervous system disorders, pain management, respiratory ailments, and oncology. In the central nervous system sector, prominent products include Copaxone, intended for relapsing forms of multiple sclerosis; AJOVY, prescribed for preventing migraines; and AUSTEDO, which targets tardive dyskinesia and chorea linked to Huntington's disease. For respiratory conditions, Teva offers medications such as ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick, all designed to treat asthma and chronic obstructive pulmonary disease. The oncology portfolio features therapies like Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited is also engaged in a collaboration with MedinCell to advance and commercialize multiple long-acting injectable formulations, notably a risperidone suspension for individuals affected by schizophrenia. The company was established in 1901 and its primary headquarters are located in Tel Aviv-Yafo, Israel.